NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Monday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets dropped their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 5.4 %

Shares of NYSE:NBY opened at $0.68 on Monday. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $11.45. The stock’s 50 day moving average is $0.67 and its 200-day moving average is $1.51. The firm has a market capitalization of $3.34 million, a price-to-earnings ratio of -0.01 and a beta of 0.73.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.